RAPS and the National University of Singapore have announced the official launch of their joint Graduate Certificate in Medical Devices Regulatory Affairs program.
The Regulatory Affairs Professionals Society (RAPS) and the National University of Singapore (NUS) have announced the official launch of their joint Graduate Certificate in Medical Devices Regulatory Affairs (MDRA) program. The program is intended for Singapore-based regulatory professionals, and was developed in partnership with the government of Singapore to cultivate an industry-ready regulatory workforce.
“Singapore has become an important center for biomedical research and business today,” said RAPS Executive Director Sherry Keramidas, PhD, FASAE, CAE. “This program will be the first to offer instruction specifically designed to develop the medical device regulatory knowledge that is in high demand by the global companies located there.”
The MDRA program builds the foundational knowledge, critical thinking and application skills required of regulatory professionals. The curriculum will be delivered through a combination of online training, interactive seminars, peer interaction and case-based learning, and will cover regulations of ASEAN nations, China, the Asia-Pacific region, the US and Europe.
The program draws on the teaching and research excellence of NUS’ biomedical engineering faculty and the real world expertise of RAPS’ renowned regulatory leaders from around the world.
Enrollment is open from now until 8 August. Visit www.bioeng.nus.edu.sg/edu/mdra.html for full program details and application information, or contact the RAPS Pan-Asia office at [email protected] or Tel: +65 6496 5507.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.